NYSE and NASDAQ Stock Price Targets and Analyst Ratings

Stay on top of the latest NYSE- and NASDAQ-listed stock analyst recommendations with our up-to-date list of stock price targets and analyst ratings. This page tracks newly issued analyst ratings, price targets, upgrades, downgrades, and other broker actions to help you see how Wall Street analysts view U.S. companies. Use these ratings to compare sentiment, spot shifts in outlook, and make more informed investment decisions.

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
A Agilent Technologies	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$136.08 +0.4%		Peer Perform
ABVX Abivax	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Julian Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$129.69 -2.2%	$150.00	Buy
ABVX Abivax	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faisal Khurshid Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$129.69 -2.2%	$90.00	Hold
ABVX Abivax	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$129.69 -2.2%		Outperform
ACRE Ares Commercial Real Estate	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marissa Lobo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.93 -0.3%	$5.50
AESI Atlas Energy Solutions	Upgraded by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$17.13 +2.7%	$25.00	Outperform
ALT Altimmune	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$3.01 -1.3%		Market Outperform
ARXS Arxis	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Godyn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$43.10 -4.1%		Buy
ASST Strive	Initiated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$17.20 -2.7%		Buy
ASTH Astrana Health	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.76 +0.4%	$50.00	Buy
A gold storm is coming – are you ready? (Ad) The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following suit ahead of what could be a massive market shift. But they're not buying bullion or coins. They're loading up on a niche asset with far more upside potential - and the details are available right now. See exactly which gold play they're targeting before the move happens
BTSG BrightSpring Health Services	Reiterated by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$59.98 -2.8%	$71.00	Overweight
BWA BorgWarner	Reiterated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colin Langan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$70.99 -1.2%		Overweight
BXMT Blackstone Mortgage Trust	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marissa Lobo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$17.94 -1.9%	$21.00
CAT Caterpillar	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$865.95 -1.1%		Neutral
CRDO Credo Technology Group	Reiterated by	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$226.10 -4.2%	$300.00	Buy
CRDO Credo Technology Group	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Blayne Curtis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$226.10 -4.2%	$270.00	Buy
CRWV CoreWeave	Initiated by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stefan Slowinski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$124.82 +14.0%	$192.00	Outperform
DUK Duke Energy	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$119.82 -2.4%		Buy
ED Consolidated Edison	Reiterated by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Crowdell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$103.69 -1.8%	$105.00	Outperform ➝ Neutral
ENHA Enhanced Group	Target Set by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$2.91 -3.4%	$6.00
FRSH Freshworks	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$10.68 +10.0%		Market Outperform
FULC Fulcrum Therapeutics	Downgraded by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$6.42 -7.2%	$3.00	Overweight ➝ Underweight
FULC Fulcrum Therapeutics	Downgraded by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$6.42 -7.2%	$3.00	Buy ➝ Neutral
FULC Fulcrum Therapeutics	Target Set by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$6.42 -7.2%	$4.00
GH Guardant Health	Upgraded by	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$129.14 -0.4%		Outperform
GNSS Genasys	Target Raised by	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Woo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2.11 -1.9%	$5.50 ➝ $6.00	Buy
GOOG Alphabet	Reiterated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$372.58 -1.0%	$435.00	Overweight
GWRE Guidewire Software	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allan Verkhovski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$171.98 +12.6%	$200.00	Buy
IBRX ImmunityBio	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andres Y. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.24 -3.7%	$15.00	Buy
IDYA IDEAYA Biosciences	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$28.94 -1.8%		Market Outperform
INCY Incyte	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$95.59 -1.2%		Market Perform
INR Infinity Natural Resources	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Diamond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.31 -1.7%		Buy
INTU Intuit	Downgraded by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kash Rangan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$353.76 +6.7%	$519.00 ➝ $276.00	Buy ➝ Sell
JBIO Jade Biosciences	Reiterated by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.59 -11.6%		Buy
JCI Johnson Controls International	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$134.32 +0.2%		Market Perform
LNG Cheniere Energy	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$227.94 +1.4%	$300.00	Outperform
LTH Life Time Group	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$31.29 -5.4%	$43.00	Outperform
MAC Macerich	Upgraded by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$22.32 -0.9%	$27.00	Buy
MANE Veradermics	Initiated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Serge Belanger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$101.96 +1.0%	$136.00	Buy
MELI MercadoLibre	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marvin Fong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,730.98 +2.1%	$2,150.00	Buy
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today
META Meta Platforms	Target Set by	Arete Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rocco Strauss Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$600.47 -5.1%	$735.00
MLM Martin Marietta Materials	Target Set by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$570.80 -1.9%	$556.00
MOBI Mobia Medical	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$13.50 +3.1%		Outperform
MOBI Mobia Medical	Initiated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.50 +3.1%	$19.00	Buy
MOBI Mobia Medical	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.50 +3.1%	$31.00	Buy
MOBI Mobia Medical	Initiated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.50 +3.1%	$16.00	Buy
MSM MSC Industrial Direct	Reiterated by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Newman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$111.76 +2.1%		Overweight
MTD Mettler-Toledo International	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,184.17 +0.3%		Peer Perform
NBIS Nebius Group	Initiated by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stefan Slowinski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$264.51 +14.5%	$255.00	Neutral
NBIX Neurocrine Biosciences	Reiterated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Corinne Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$161.00 +1.7%	$213.00	Buy
NU NU	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mario Pierry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$12.97 -1.3%		Neutral ➝ Underperform
ODTX Odyssey Therapeutics	Initiated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$16.96 -0.3%		Buy
ODTX Odyssey Therapeutics	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$16.96 -0.3%		Overweight
ODTX Odyssey Therapeutics	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Jones Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.96 -0.3%	$40.00	Outperform
OPTU Optimum Communications	Upgraded by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$1.18 +78.5%		Neutral
ORCL Oracle	Reiterated by	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$247.45 +9.6%		Sector Outperform
PRAX Praxis Precision Medicines	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$335.16 -4.2%	$1,245.00 ➝ $1,201.00	Buy
PRAX Praxis Precision Medicines	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$335.16 -4.2%	$433.00 ➝ $400.00	Outperform
PRAX Praxis Precision Medicines	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$335.16 -4.2%	$374.00	Buy
PRAX Praxis Precision Medicines	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kambiz Yazdi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$335.16 -4.2%	$843.00 ➝ $810.00	Buy
QBTS D-Wave Quantum	Reiterated by	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$29.17 -3.2%		Buy
QBTS D-Wave Quantum	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Quinn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.17 -3.2%	$40.00	Buy
RACE Ferrari	Reiterated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$349.18 +2.6%		Outperform
RAPP Rapport Therapeutics	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$37.11 -6.1%		Market Outperform
RGEN Repligen	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$123.10 -0.7%	$145.00	Outperform
RIGL Rigel Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.86 -2.1%	$57.00	Buy
RPD Rapid7	Upgraded by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Meta Marshall Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.74 +4.3%		Outperform ➝ Neutral
RVTY Revvity	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$100.44 -3.9%		Peer Perform
SAIA Saia	Reiterated by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$482.22 +2.1%		Neutral
SAIL SailPoint	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Saket Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.25 +2.2%	$22.00	Overweight
SARO StandardAero	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$27.39 -4.4%		Hold
SHW Sherwin-Williams	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Spector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$295.02 -2.9%	$330.00	Buy ➝ Neutral
SQM Sociedad Quimica y Minera	Upgraded by	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$83.53 -2.7%		Outperform
SQM Sociedad Quimica y Minera	Target Set by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$83.53 -2.7%	$100.00
STRL Sterling Infrastructure	Reiterated by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sangita Jain Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$845.39 -1.8%		Overweight
STVN Stevanato Group	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	€18.86 -0.1%	$21.00	Outperform
STWD Starwood Property Trust	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marissa Lobo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.81 -1.6%	$20.00
TFII TFI International	Reiterated by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$156.33 +1.4%		Positive
TMHC Taylor Morrison Home	Downgraded by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Dahl Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$71.55 +22.3%		Outperform ➝ Sector Perform
TMO Thermo Fisher Scientific	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$493.18 +0.1%	$535.00	Outperform
VMC Vulcan Materials	Target Set by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$281.52 -0.5%	$283.00
WAT Waters	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$376.97 -1.7%	$425.00	Outperform
WDC Western Digital	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asiya Merchant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$546.20 +2.8%		Buy
WS Worthington Steel	Reiterated by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samuel McKinney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.66 +1.1%		Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:43 AM ET.

Frequently Asked Questions

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NYSE and NASDAQ Stock Price Targets and Analyst Ratings

Frequently Asked Questions